CV6 Therapeutics to invest almost £8m in clinical trial for new anti-cancer drug.
Congratulations to our new portfolio company, CV6 Therapeutics, on securing a landmark £8m of equity and grant funding to support the commencement of first-stage clinical trials and further scientific development work on its first anti-cancer drug CV6-168. Article taken from: https://www.investni.com/ Pictured above are: Ian Greer, Robert Ladner and Mel Chittock. CV6 is dedicated to […]
CV6 Therapeutics to invest almost £8m in clinical trial for new anti-cancer drug. Read More »









